Asymptomatic COVID-19 Re-infection in a Japanese Male by Elevated Half-Maximal Inhibitory Concentration (IC50) of Neutralizing Antibodies
Autor: | Mari Terada, Satoshi Kutsuna, Mugen Ujiie, Kenji Maeda, Makoto Inada, Akihiro Matsunaga, Masahiro Ishikane, Hiroaki Mitsuya, Yu Sairenji, Kiyoto Tsuchiya, Noriko Kinoshita, Norio Ohmagari, Kenji Miura, Yukihito Ishizaka |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Microbiology (medical) Male 030106 microbiology Antibodies Viral Asymptomatic Virus Serology 03 medical and health sciences 0302 clinical medicine Japan medicine Humans Pharmacology (medical) 030212 general & internal medicine Viral shedding Neutralizing antibody First episode re-infection biology business.industry SARS-CoV-2 COVID-19 neutralizing antibody anti-Spike protein IgG antibody Middle Aged medicine.disease Antibodies Neutralizing respiratory tract diseases Pneumonia Infectious Diseases Reinfection Immunology biology.protein Original Article medicine.symptom Antibody business |
Zdroj: | Journal of Infection and Chemotherapy |
ISSN: | 1437-7780 1341-321X |
Popis: | Introduction “Re-infection” with COVID-19 is a growing concern; re-infection cases have reported worldwide. However, the clinical characteristics of SARS-CoV-2 re-infection, including the levels and role of anti-SARS-CoV-2 Spike protein IgG antibodies and the half-maximal concentration (IC50) of neutralizing antibodies remain unknown. Methods Both the epidemiological and clinical information has been collected during two episodes of COVID-19 in a patient. Laboratory results, including RT-PCR, Ct values, anti-SARS-CoV-2 Spike protein IgG antibodies, and the IC50 of neutralizing antibodies levels were analyzed on the patient. Results The patient was a 58-year-old man who developed moderate COVID-19 pneumonia with oxygen demand (cannula 2 L/min) in the first episode. By day 30, he recuperated and was discharged after testing negative for SARS-CoV-2. After two and a half months, his three family members showed COVID-19 symptoms and tested positive for SARS-CoV-2. He tested positive for SARS-CoV-2 once again and was asymptomatic (the second episode). The IC50 of neutralizing antibodies against SARS-CoV-2 greatly increased from 50.0 μg/mL (after the first episode) to 14.8 μg/mL (after the second episode), and remained strongly reactive (20.1 μl/mL) after 47 days of the second episode. Conclusions Epidemiological, clinical, and serological analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Our results suggest that SARS-CoV-2 re-infection may manifest as asymptomatic with increased neutralizing antibody levels. Further studies such as the virus characteristics, immunology, and epidemiology on SARS-CoV-2 re-infection are needed. |
Databáze: | OpenAIRE |
Externí odkaz: |